CWBR - The Buzz Show: CohBar Inc. (NASDAQ: CWBR) Results from the Phase 1a/1b Study of CB4211

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “CohBar, Inc. Rose 52% Following Positive Topline Results from the Phase 1a/1b Study of CB4211”

CohBar, Inc (NASDAQ: CWBR) surged over 52% in premarket trading after the company announced positive topline results from the Phase 1a/1b Study of CB4211.

Under development for nonalcoholic steatohepatitis and obesity, the study of CB4211 met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events.

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases.

For more information, please visit: CohBar, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: CohBar, Inc. (NASDAQ: CWBR) Results from the Phase 1a/1b Study of CB4211 first appeared on Financial Buzz .

For further details see: